NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

This roundtable series examines therapy for patients with metastatic small cell lung cancer after first-line therapy, as discussed by key opinion leaders at virtual live events and interviews.

Small Cell Lung Cancer Treated in Second Line and Later

Addition of Lurbinectedin Improves Duration of Maintenance in ES-SCLC

Addition of Lurbinectedin Improves Duration of Maintenance in ES-SCLC

January 12, 2026

During a live event, Joshua K. Sabari, MD, discussed subgroup analyses and safety outcomes of the IMforte trial in extensive-stage small cell lung cancer.

Lurbinectedin Contributes to Maintenance of Response in ES-SCLC

Lurbinectedin Contributes to Maintenance of Response in ES-SCLC

December 04, 2025

During a live event, Joshua K. Sabari, MD, discussed outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

Evaluating Which Patients Benefit From Maintenance Chemo in ES-SCLC

Evaluating Which Patients Benefit From Maintenance Chemo in ES-SCLC

November 05, 2025

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

IMforte Trial Maintenance Regimen Extends Survival for ES-SCLC

IMforte Trial Maintenance Regimen Extends Survival for ES-SCLC

October 23, 2025

During a live event, Wade T. Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.